Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic ...

Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in ...

WALTHAM, Mass., July 03, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody ...

WALTHAM, Mass., July 03, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the 'Company” or 'Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody ...

In a report released yesterday, Faisal Khurshid from Leerink Partners reiterated a Buy rating on Zura Bio. The company’s shares closed yesterday at $1.96. Elevate Your Investing ...

View the latest Spyre Therapeutics Inc. (SYRE) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Review the current Spyre Therapeutics Inc (SYRE:XNAS) dividend yield and history to decide if SYRE is the best investment for you.